As mentioned above, due to the importance of the CDK4/6-USP51 signaling pathway in the treatment of advanced breast cancer, we selected this signaling pathway for this study to investigate whether ribociclib affects the mRNA expression of genes involved in this pathway. Here, CDK4 is linked to breast carcinoma.